Avantor, Inc. announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease.
Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at Scale
RADNOR, Pa., July 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease.
“These products help gene therapy manufacturers improve harvest while preserving the quality and integrity of highly valuable viral particles,” said Benoit Gourdier, Executive Vice President of Bioscience Production at Avantor. “These products also respond to growing demand from biopharmaceutical customers for environmentally sustainable options.”
Avantor scientists developed J.T.Baker® Cell Lysis Solution as a safe and effective alternative to Octoxynol-9, which is on the European Chemicals Agency’s “substance of very high concern” list under REACH regulations given concerns that it is toxic to aquatic life when entering the environment through waste systems.
J.T.Baker® Cell Lysis Solution is biodegradable and exhibits low ecotoxicity when used in the upstream harvesting process to release adeno-associated virus (AAV) from host cells, a pivotal step in gene therapy workflows. Avantor® studies1 show that the solution improves the efficiency of viral vector release across a range of cell densities and temperatures while protecting the viral particles from damage during processing.
As a ready-to-use reagent that does not require refrigeration or advanced preparation, the J.T.Baker® Cell Lysis Solution streamlines the harvest process and minimizes contamination risk by eliminating the need for pre-dilution and filtration, significantly reducing bioburden risk. The solution’s high-concentration formulation also lowers viscosity and foam generation to reclaim valuable bioreactor space.
Pairing J.T.Baker® Cell Lysis Solution with compatible J.T.Baker® Endonuclease — an enzyme that removes remaining impurities — can further reduce the number of steps at harvest, enabling a more efficient process. Working together to provide robust DNA clearance and reduced aggregation, these solutions can be customized for any scale with a wide range of cGMP grade size options.
Avantor’s J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease are part of a full range of modular and scalable chemical and fluid handling solutions. For additional product information, please visit our web site.
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
Global Media Contact
Emily Collins
Vice President, External Communications
Avantor
332-239-3910
Emily.Collins@avantorsciences.com
Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com
1 Novel Cell Lysis Solution: Scaling up the harvest process while preserving what matters, Kroeger-Fahnestock, 2024
View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-announces-new-jtbaker-cell-lysis-solution-and-jtbaker-endonuclease-302186455.html
SOURCE Avantor and Financial News
Company Codes: NYSE:AVTR